RBC Capital Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $198

RBC Capital analyst Brian Abrahams maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Outperform and raises the price target from $195 to $198.